Jenny Zhang China

Cro
Partnering Objectives
Headquartner in China
Tigermed
Head 

Dr. Tong Zhang China

Company Size (Fulltime employees)
Year of foundation
2002
Please specify your partnering goal
Global partnership on Genechem preclinical assets
Headquartner in China
Biotech/Pharma Category
Assets Information 1
Claudin 6 Ab
Assets Information 2
Kras-TCRT
Biotech/Pharma Asset Stage
GeneChem
Chief Business Officer 

Jing Zhang China

Phamaceutical company focus on innovative drugs including oncology, neurology and autoimmune diseases.
Website:
simcere. com
Partnering Objectives
Headquartner in China
Simcere
Manager 

Dr Fang Zhang China

An international enterprise dedicated to the innovation, ptoduce and selling of innovative drugs
Company Size (Fulltime employees)
Please specify your partnering goal
more RA knowledge
Headquartner in China
Luye pharma
Senior Business Development Manager 

Mingzhu Zhang China

CRO based in Shanghai
Company Size (Fulltime employees)
Partnering Objectives
Please specify your partnering goal
Working with clients with preclinical R&D needs
Headquartner in China
Shanghai Medicilon
VP of Business Development  

Han Zhang China

China based company with focusing on psychiatry.
Website:
WWW.Foncoo.com
Partnering Objectives
Headquartner in China
Biotech/Pharma Category
Shenzhen Foncoo Pharmaceutical
Business Development Manager 

Mr Elvis Zhang China

L.E.K. Consulting is a global management consulting firm that uses deep industry expertise and rigorous analysis to help business leaders achieve practical results with real impact. Founded 38 years ago, L.E.K. employs more than 1,400 professionals around the world. L.E.K. entered China in 1998 and has since become a leading commercial advisor in life sciences and healthcare services practices, covering all aspects of the industry value chain and life cycle. Supported by the Singapore Economic Development Board, L.E.K. established The APAC Life Sciences Centre of Excellence, aiming to provide life sciences companies in APAC with useful insights and practical knowledge, including best practices from other markets around the world. For more information, go to www.lek.com

Website:
www.lek.com
Company Size (Fulltime employees)
Year of foundation
1983
Partnering Objectives
L.E.K.
Business Development Director 

Xiaoyuan Zhang China

Mabwell, founded in 2017 in Zhangjiang District of Shanghai, is an innovation-based bio-pharmaceutical company with 9 biomedical R&D and manufacturing subsidiaries and a strong, diverse and experienced technical team under its wing. With its world class high-throughput antibody drug discovery platform, well-established pharmaceutical research system and mature process development, the company is dedicated to the R&D and manufacturing of therapeutic monoclonal antibodies, long acting recombinant protein and other new macromolecular drugs. Currently, 30 different drugs for tumor, autoimmunity, infection resistance and ophthalmology are being developed at various stages, among which 1 is cleared for production and 6 are in clinical research with 4 in key clinical stage. Guided by an innovation-driven strategy, the company has actively pushed for commercialization with a production facility built in line with both Chinese and Western GMP standards already up and running in Taizhou, Jiangsu province. Another large-scale industrial base in Shanghai is under construction. The first drug variety will be on the market in 2020 and the number will go up to 4 (or more) in 2023, Mabwell closed series A financing of 1.97 Billion Yuan at April, 2020, demonstrating the company’s ambition to become a leading bio-pharmaceutical enterprise in China.
Website:
www.mabwell.com
Partnering Objectives
Headquartner in China
Mabwell Bio
BD Director 

Xinzhi Zhang China

Medprin focuses on RD and sales and marketing of implantable medical devices with products in general surgery and neurosurgery. Current Medprin is actively looking for promising startups /team with matching technology/products that Medprin can both invests financially and develops long term partnership.
Website:
www.medprin.com
Partnering Objectives
Headquartner in China
Medprin Regenerative Technologies
Senior Manager of Business Development 

Mr. Song Zhang China

CTS Capital was founded in 2017. As a private equity firm, CTS Capital focuses on investment opportunities in the biotechnology and healthcare services industries. CTS Capital is managed by a team of professionals with deep industry knowledge, extensive experiences in private equity and global strategic insights. Driven by our team’s business acumen and investment expertise, CTS Capital has made investments in companies at the cutting edge of the biotechnology and healthcare industries, including innovative drugs, medical devices, diagnostics, gene technology, digital health and AI in healthcare,etc.
We employ a research-driven investment approach and collaborate closely with our companies to build lasting and impactful businesses in the life sciences and healthcare industries. We are committed to working in close partnership with the top innovative pharmaceutical, biotech and medical technology companies to promote biotechnology innovation and healthcare transformation in China.
Company Size (Fulltime employees)
Year of foundation
2017
Please specify your partnering goal
Looking for clients and partners in Pharmaceutical,Biotechnology,Medical Devices and Sevices
Headquartner in China
CTS Capital
CEO 
Functionality